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Abstract
Background: TBI biomarkers display population-level time-varying kinetics [1] which may be a rich source of
pathobiological information [2]. At an individual level, deviations from stereotypical trajectories may 
represent different pathological processes or secondary insults. A method for discovering such phenotypes 
may be useful in individualising treatments in real-time.
Method: Serial blood (12hourly) and CSF (6hourly) samples were obtained from seventeen adult patients 
with severe TBI (Stockholm ethics committee approval #2009/1112-31). S100B and neuron-specific enolase 
(NSE) concentrations were measured along with blood:CSF albumin quotient Qa as a measure of blood-
brain-barrier (BBB) integrity. S100B and NSE concentrations were log-transformed: Equivalent to the 
assumption of baseline exponential decay. We used trajectory modeling combining a quadratic mixed 
effects model with latent group analysis to search for characteristic trajectories in the measured parameter.
Results: For serum S100B, we discovered two phenotypes with fast and slow kinetics. The fast group 
corresponded with patients with more severe extracranial injury. For serum NSE, again two phenotypes 
were discovered; a time-decaying group and another with a peak around day 4. 
CSF analysis yielded two latent groups for both S100B and NSE: a time-decaying group and another 
displaying prolonged elevation over several days. 
Qa data clustered into three groups: two with fast, slow decay and another with prolonged elevation. The 
group with prolonged BBB permeability had corresponding poorer outcomes.
Conclusions: Small numbers prevent statistical comparison, but trajectory modeling identified a number of 
phenotypes with plausible pathobiological significance. In particular the technique revealed a group of 
patients with secondary serum NSE release and another with sustained BBB permeability. Such groups seem
to relate to injury profile and outcome suggesting biological relevance. To our knowledge this is the first use 
of an unsupervised clustering technique in kinetic phenotype discovery.
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